English 
Ono Pharmaceutical Co., Ltd. announced that it has entered into a research collaboration agreement with Jorna Therapeutics in December 2024 aimed at drug discovery using Jorna’s proprietary ribonucleic acid (RNA) editing platform. Having completed the validation of this platform, Ono has begun the search for nucleic acid sequences that could serve as drug candidates.
本契約に基づき、ジョルナ社は、量子力学に基づくAI「SkyEngine」をベースとした独自のタンパク質・RNA生成AIモデルを用いて、RNA編集薬の配列を設計します。小野薬品は、ジョルナ社が設計した塩基配列から創製される医薬品候補化合物の発見、開発、商品化に関する全世界での独占的オプション権を有します。小野薬品は、既にジョルナ社に支払った契約一時金に加え、研究資金や研究の進捗に応じたマイルストンを支払います。
こちらもお読みください： B-EN-G、製薬企業向けMES「BatchLine Lite」を販売開始
“We highly value Jorna’s unique generative AI technologies, which combine large-scale amino acid sequence information and language models to design desired proteins,” said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono. “Through this partnership, we aim to accelerate drug development using RNA editing technology and provide new treatment options to patients around the world with unmet medical needs.”
“We are delighted to collaborate with Ono to advance our shared vision of delivering groundbreaking therapies to patients. This partnership is expected to accelerate efforts to bring RNA editing-based therapies to market by leveraging 小野‘s global resources and expertise,” said Chengwei Luo, Founder and CEO of ジョルナ.
ソース ビジネスワイヤー
日本語